peoplePerson
Eunice S. Wang
Eunice Wang is an AML trialist who helped bring FLT3 and menin inhibitors to patients.
Leads leukaemia clinical research at Roswell Park; investigator on gilteritinib, quizartinib and menin inhibitor studies and NCCN AML panel member.
Role
Chief, Leukemia Service
Institution
Specialisms
Acute myeloid leukaemiaFLT3 inhibitorsNovel leukaemia agents
Profiles
| Title | Journal | Year |
|---|---|---|
| Crenolanib for FLT3-mutated AML | Blood Advances | 2021 |
Pages like this
not linked directly; found by shared links- TrialADMIRAL
Shares Gilteritinib, FLT3, Acute myeloid leukaemia.
- CompanySyndax Pharmaceuticals
Shares Revumenib, Acute myeloid leukaemia.
- TrialAUGMENT-101
Shares Revumenib, Menin, Acute myeloid leukaemia.
- PairingFLT3 inhibitor + intensive chemotherapy
Shares Gilteritinib, FLT3, Acute myeloid leukaemia.
- PairingMenin inhibitor + venetoclax + azacitidine
Shares Revumenib, Menin, Acute myeloid leukaemia.
- TargetNPM1 mutation
Shares FLT3, Revumenib, Menin, Acute myeloid leukaemia.
- TermDifferentiation syndrome
Shares Gilteritinib, Revumenib, Menin, Acute myeloid leukaemia.
- Key paperADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia
Shares Gilteritinib, FLT3, Acute myeloid leukaemia.